A regulatory perspective on missing data in the aftermath of the NRC report.
about
Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem.Commentary for the Missing Data Working Group's perspective for regulatory clinical trials, estimands, and sensitivity analyses.Missing data in clinical trials: control-based mean imputation and sensitivity analysis.Estimands in clinical trials - broadening the perspective.Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
P2860
A regulatory perspective on missing data in the aftermath of the NRC report.
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A regulatory perspective on missing data in the aftermath of the NRC report.
@ast
A regulatory perspective on missing data in the aftermath of the NRC report.
@en
type
label
A regulatory perspective on missing data in the aftermath of the NRC report.
@ast
A regulatory perspective on missing data in the aftermath of the NRC report.
@en
prefLabel
A regulatory perspective on missing data in the aftermath of the NRC report.
@ast
A regulatory perspective on missing data in the aftermath of the NRC report.
@en
P2860
P356
P1476
A regulatory perspective on missing data in the aftermath of the NRC report.
@en
P2093
Lisa M LaVange
Thomas Permutt
P2860
P356
10.1002/SIM.6840
P407
P577
2015-12-17T00:00:00Z